癌症藥物市場：依藥物類別、適應症和地區分類

Cancer Drugs Market, By Drug Class Type and By Indication By Geography

出版日期: 2026年03月26日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年癌症藥物市場規模為1,927億美元，預計到2033年將達到3,260億美元。預計2026年至2033年，該市場將以7.8%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	1927億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.80%	2033年市場規模預測：	3260億美元

癌症是最致命的疾病之一，其特徵是體內某些細胞不受控制地生長並轉移到身體其他部位。針對不同類型的癌症，目前有多種治療方法，包括化療、荷爾蒙療法、分子標靶藥物、免疫療法和雙磷酸鹽類藥物。隨著癌症負擔的加重，全球對安全有效的癌症治療方法的需求也迅速成長。

市場動態

癌症發病率不斷上升、老年人口不斷成長、對安全有效的癌症治療需求旺盛、公眾對癌症和癌症治療的認知不斷提高以及癌症治療中心數量增加等因素，預計將在預測期內推動全球癌症治療市場的成長。

例如，根據美國癌症協會（ACS）的數據，預計2023年美國將新增超過1958,310例癌症病例，並有609,820例癌症死亡病例。相較之下，2022年美國預計將新增約19億例癌症病例，並有609,360例癌症死亡病例。此外，根據印度醫學研究理事會（ICMR）的癌症報告，未來五年印度的癌症患者人數可能增加12%，到2026年，將有約15億人患有這種非傳染性疾病，高於2021年的13.9億人。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據公司亮點、產品系列、主要特點、財務表現和策略等參數，創建了全球癌症治療市場主要公司的概況。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份全球癌症治療市場報告的目標受群眾外包括行業內的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
透過利用全球癌症藥物市場分析中使用的各種策略矩陣，相關人員可以更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 192.70 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	7.80%	2033 Value Projection:	USD 326 Bn

Cancer is a most lethal disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. Cancer drugs, such as chemotherapy, hormone therapies, targeted cancer drugs, immunotherapy drugs, and bisphosphonates, among others, are used to treat different types of cancer. Thus, with the rise in burden of cancer, the demand for safe and effective cancer drugs is also increasing with a rapid pace, worldwide.

Market Dynamics

Increasing prevalence of cancer, growing geriatric population, high demand for safe and effective cancer drugs, increasing awareness among people about a cancer and cancer drugs, and increasing number of cancer treatment centres are factors expected to augment the growth of the global cancer drugs market during the forecast period.

For instance, according to the American Cancer Society (ACS), in 2023, more than 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. While, in 2022, around 1.9 Billion new cancer cases and 609,360 cancer deaths were projected to occur in the U.S. Moreover, according to the cancer report by Indian Council of Medical Research (ICMR), India's cancer cases could increase by 12% in the next five years, with around 1.5 Billion people projected to suffer from the non-communicable disease by 2026, up from 1.39 Billion in 2021.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson (Janssen Global Services, LLC), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer drugs market.

Market Segmentation

Global Cancer Drugs Market, By Drug Class Type (Revenue, USD Bn, 2021 - 2033)
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Global Cancer Drugs Market, By Indication (Revenue, USD Bn, 2021 - 2033)
Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancer
Global Cancer Drugs Market, By Geography (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
Key Players Insights
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Celgene Corporation
AstraZeneca PLC
Astellas Pharma Inc.
AbbVie Inc.
Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
Johnson & Johnson (Janssen Global Services, LLC)

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class Type
- Market Snapshot, By Indication
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing burden of cancer across the globe
- Adverse effects of cancer drugs
- Growing demand for safe and effective drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Cancer Drugs Market, By Drug Class Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Immunotherapy (Biologic Therapy)
Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Hormonal Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Cancer Drugs Market, By Indication, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Stomach Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Liver Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Esophagus Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cervical Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Kidney Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Other Cancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Cancer Drugs Market, By Region, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)

7. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson (Janssen Global Services, LLC)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views